168 related articles for article (PubMed ID: 35434851)
1. Susceptibility testing alone will not reliably achieve high Helicobacter pylori cure rates: A systematic review and meta-analysis.
Huang Y; Chen J; Ding Z; Liang X; Lu H
J Gastroenterol Hepatol; 2022 Jul; 37(7):1212-1221. PubMed ID: 35434851
[TBL] [Abstract][Full Text] [Related]
2. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
3. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
[TBL] [Abstract][Full Text] [Related]
4. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
5. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication.
Gisbert JP; Gonzalez L; Calvet X
Helicobacter; 2005 Jun; 10(3):157-71. PubMed ID: 15904473
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance.
Park CS; Lee SM; Park CH; Koh HR; Jun CH; Park SY; Lee WS; Joo YE; Kim HS; Choi SK; Rew JS
Am J Gastroenterol; 2014 Oct; 109(10):1595-602. PubMed ID: 25091062
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis.
Lin K; Huang L; Wang Y; Li K; Ye Y; Yang S; Li A
Helicobacter; 2023 Dec; 28(6):e13015. PubMed ID: 37634236
[TBL] [Abstract][Full Text] [Related]
9. Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced?
Baylina M; Muñoz N; Sánchez-Delgado J; López-Góngora S; Calvet X; Puig I
Helicobacter; 2019 Jun; 24(3):e12584. PubMed ID: 30990575
[TBL] [Abstract][Full Text] [Related]
10. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
[TBL] [Abstract][Full Text] [Related]
11. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.
Prasertpetmanee S; Mahachai V; Vilaichone RK
Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori.
Gisbert JP; González L; Calvet X; García N; López T; Roqué M; Gabriel R; Pajares JM
Aliment Pharmacol Ther; 2000 Oct; 14(10):1319-28. PubMed ID: 11012477
[TBL] [Abstract][Full Text] [Related]
13. Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy.
Gisbert JP; González L; Calvet X; Roqué M; Gabriel R; Pajares JM
Aliment Pharmacol Ther; 2000 Sep; 14(9):1141-50. PubMed ID: 10971230
[TBL] [Abstract][Full Text] [Related]
14. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
Sugimoto M; Uotani T; Sahara S; Ichikawa H; Yamade M; Sugimoto K; Furuta T
Helicobacter; 2014 Aug; 19(4):312-8. PubMed ID: 24690010
[TBL] [Abstract][Full Text] [Related]
16. Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies.
Sezgin O; Aydın MK; Özdemir AA; Kanık AE
Turk J Gastroenterol; 2019 May; 30(5):420-435. PubMed ID: 31060997
[TBL] [Abstract][Full Text] [Related]
17. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole.
Janssen MJ; Van Oijen AH; Verbeek AL; Jansen JB; De Boer WA
Aliment Pharmacol Ther; 2001 May; 15(5):613-24. PubMed ID: 11328254
[TBL] [Abstract][Full Text] [Related]
18. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
Digestion; 2020; 101(5):644-650. PubMed ID: 31387107
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study.
Kim SY; Lee SW; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Lee HS; Choi JH; Kim CD; Ryu HS
Helicobacter; 2008 Aug; 13(4):282-7. PubMed ID: 18665938
[TBL] [Abstract][Full Text] [Related]
20. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough.
Gisbert JP; Calvet X
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1255-68. PubMed ID: 22017749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
